2019 + 2020 Annual Report
Driving Development of New Symptomatic Treatments
IN PART BECAUSE OF THE COMPLEXITY and variability of Parkinson ’ s disease , it is a priority to have more options to treat symptoms . The number of treatments in later stages of development and getting to pharmacy shelves is increasing at an unprecedented pace , offering Parkinson ’ s patients and the physicians who treat them more options to manage the disease and live well with PD .
The Foundation ’ s in-house team of scientists , working in concert with a worldwide who ’ s who of Parkinson ’ s research groups , is focused on identifying and accelerating the development of therapies targeting critical stages and symptoms of PD . Therapies addressing motor and non-motor symptoms that can impact quality of life such as movement challenges , cognitive impairment , gait and balance issues , and mood changes , to name a few , are actively monitored each year to and the subject of significant funding each year .
Since 2014 , more than a dozen new treatments ( drugs and medical devices ) have been approved by the U . S . Food and Drug Administration ( FDA ) to treat the symptoms of Parkinson ’ s — these treatments represent a wide array of therapeutic approaches to meet a range of medical needs .
Pipeline in Real Time : The Next Trial Results We ’ re Expecting
The research and patient communities are awaiting important results from the following trials in 2021 :
+ Takeda and AstraZeneca : Co-developers of a drug to break up alpha-synuclein protein clumps in a Phase I trial expected to report results soon .
+ Prevail Therapeutics and Eli Lilly : Expected to share interim data on their Phase I / II trial testing a GBA pathway therapy this year . ( Eli Lilly acquired Prevail in 2020 .)
+ Denali and Biogen : After positive safety and biomarker results from a Phase I trial , the partners are launching a later-stage trial of their LRRK2 drug by year-end .
+ Alkahest and Grifols : MJFF grantee Alkahest , acquired by Spanish pharma firm Grifols in 2020 , aim to share findings from their Phase II trial targeting inflammation in the brain .
11